1679 related articles for article (PubMed ID: 17692296)
1. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
2. Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
Crain SM; Shen KF
Brain Res; 2008 Sep; 1231():16-24. PubMed ID: 18656459
[TBL] [Abstract][Full Text] [Related]
3. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence.
Shen KF; Crain SM
Brain Res; 2001 Nov; 919(1):20-30. PubMed ID: 11689159
[TBL] [Abstract][Full Text] [Related]
4. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia.
Crain SM; Shen KF
Brain Res; 2001 Jan; 888(1):75-82. PubMed ID: 11146054
[TBL] [Abstract][Full Text] [Related]
5. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Crain SM; Shen KF
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
Shen KF; Crain SM
Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
[TBL] [Abstract][Full Text] [Related]
7. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
Crain SM; Shen KF
Brain Res; 1996 Nov; 741(1-2):275-83. PubMed ID: 9001733
[TBL] [Abstract][Full Text] [Related]
8. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
Sinchaisuk S; Ho IK; Rockhold RW
Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
[TBL] [Abstract][Full Text] [Related]
9. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
10. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
Juni A; Klein G; Kest B
Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice.
Crain SM; Shen KF
Brain Res; 2004 Jan; 995(2):260-6. PubMed ID: 14672816
[TBL] [Abstract][Full Text] [Related]
12. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
13. Morphine-6beta-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans.
van Dorp EL; Kest B; Kowalczyk WJ; Morariu AM; Waxman AR; Arout CA; Dahan A; Sarton EY
Anesthesiology; 2009 Jun; 110(6):1356-63. PubMed ID: 19461298
[TBL] [Abstract][Full Text] [Related]
14. Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system.
Le Guen S; Gestreau C; Besson JM
Eur J Neurosci; 2003 Jun; 17(11):2425-37. PubMed ID: 12814374
[TBL] [Abstract][Full Text] [Related]
15. After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition.
Crain SM; Shen KF
J Pharmacol Exp Ther; 1992 Jan; 260(1):182-6. PubMed ID: 1731037
[TBL] [Abstract][Full Text] [Related]
16. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside.
Crain SM; Shen KF
Brain Res; 1992 Mar; 575(1):13-24. PubMed ID: 1324084
[TBL] [Abstract][Full Text] [Related]
17. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
18. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence.
Crain SM; Shen KF
Neurochem Res; 1996 Nov; 21(11):1347-51. PubMed ID: 8947924
[TBL] [Abstract][Full Text] [Related]
19. Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice.
Campillo A; Cabañero D; Romero A; García-Nogales P; Puig MM
Eur J Pharmacol; 2011 Apr; 657(1-3):89-96. PubMed ID: 21300053
[TBL] [Abstract][Full Text] [Related]
20. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
